Table 2.
Apolipoprotein B and β2-glycoprotein-I (GPI) autoantibodies in systemic lupus erythematosus (SLE) patients and controls
| SLE patients (n = 434) median (IQR)* | Controls (n = 322) median (IQR)* | P | |
|---|---|---|---|
| Apolipoprotein B antibodies | |||
| p45 IgM | 0·64 (0·30–1·29) | 0·86 (0·47–1·72) | 0·001 |
| MDA-p45 IgM | 0·72 (0·37–1·43) | 0·92 (0·56–0·92) | 0·001 |
| p45 IgG | 0·49 (0·23–1·03) | 0·42 (0·20–0·90) | n.s. |
| MDA-p45 IgG | 0·52 (0·28–1·02) | 0·43 (0·23–0·95) | n.s. |
| p210 IgM | 0·77 (0·52–1·06) | 0·70 (0·53–0·89) | 0·007 |
| MDA-p210 IgM | 0·87 (0·63–1·03) | 0·79 (0·62–0·93) | 0·002 |
| p210 IgG | 0·48 (0·24–0·84) | 0·54 (0·35–0·89) | 0·02 |
| MDA-p210 IgG | 0·70 (0·51–0·98) | 0·82 (0·61–1·05) | 0·005 |
| β2GPI antibodies | |||
| β2GPI IgM | 1·9 (1·9–3·9) | 1·9 (1·9–2·5) | 0·002 |
| β2GPI IgG | 1·9 (1·9–10·2) | 1·9 (1·9–1·9) | 0·001 |
*
Distributions are given as median [interquartile range (IQR)].
Ig = immunoglobulin; MDA = malondialdehyde; n.s. = not significant.